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ABSTRACT Cognitive deficits in human infants at risk for gestationally acquired perinatal iron deficiency suggest
involvement of the developing hippocampus. To understand the plausible biological explanations for hippocampal
injury in perinatal iron deficiency, a neurochemical profile of 16 metabolites in the iron-deficient rat hippocampus
was evaluated longitudinally by 1H NMR spectroscopy at 9.4 T. Metabolites were quantified from an 11–24 L
volume centered in the hippocampus in 18 iron-deficient and 16 iron-sufficient rats on postnatal day (PD) 7, PD10,
PD14, PD21 and PD28. Perinatal iron deficiency was induced by feeding the pregnant dam an iron-deficient diet
from gestational d 3 to PD7. The brain iron concentration of the iron-deficient group was 60% lower on PD7 and
19% lower on PD28 (P  0.001 each). The concentration of 12 of the 16 measured metabolites changed over time
between PD7 and PD28 in both groups (P  0.001 each). Compared with the iron-sufficient group, phosphocre-
atine, glutamate, N-acetylaspartate, aspartate, -aminobutyric acid, phosphorylethanolamine and taurine concen-
trations, and the phosphocreatine/creatine ratio were elevated in the iron-deficient group (P  0.02 each). These
neurochemical alterations suggest persistent changes in resting energy status, neurotransmission and myelination
in perinatal iron deficiency. An altered neurochemical profile of the developing hippocampus may underlie some of
the cognitive deficits observed in human infants with perinatal iron deficiency. J. Nutr. 133: 3215–3221, 2003.
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Human infants whose gestations were complicated by ma-
ternal iron deficiency, maternal diabetes mellitus, intrauterine
growth retardation or prematurity are at risk for perinatal iron
deficiency (1–3). Perinatal iron deficiency is associated with
long-term cognitive abnormalities (4–6). Iron plays an impor-
tant role in normal neurodevelopment through enzymes con-
trolling neurotransmitter synthesis (7), cell division (8), neu-
ronal energy metabolism (8,9) and myelination (10,11). Any
or all of these mechanisms may be perturbed in states of
perinatal iron deficiency.
Electrophysiologic studies in infants at risk for perinatal
iron deficiency suggest functional perturbations of the devel-
oping hippocampus, an area central to recognition memory
(4,5). Hippocampal development begins prenatally and con-
tinues postnatally in humans and rats (12–14). In rats, con-
tinued neurogenesis, extensive remodeling of pyramidal cell
dendrites, peak velocities of myelination and proliferation of
synapses result in an exponential increase in the size of the
hippocampus during the first four postnatal weeks (12–14).
The rapid growth rate is accompanied by upregulation of
regional iron transporters and presumably increased iron uti-
lization by the developing hippocampus (15). The accelerated
growth rate also increases the vulnerability of the developing
hippocampus to various perinatal and postnatal injuries (9,16–
19).
A perturbation in the normal development of the hip-
pocampus by perinatal iron deficiency may play a role in
cognitive abnormalities in at-risk human infants. Histochem-
ical (9) and behavioral studies (16) in rats have demonstrated
selective involvement of the developing hippocampus in peri-
natal iron deficiency.
Nevertheless, the biochemical mechanisms through which
perinatal iron deficiency specifically affects the developing
hippocampus have not been comprehensively studied. A lon-
gitudinal evaluation of neurochemical changes during hip-
pocampal development may help explain the potential path-
ways through which perinatal iron deficiency alters
hippocampal development and function. Previous studies fo-
cused on specific biochemical alterations in models of postna-
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tal iron deficiency (8,20). The invasive nature of such bio-
chemical methods precludes longitudinal study designs. In
vivo 1H NMR spectroscopy is a sensitive and noninvasive
method for simultaneous evaluation of several neurochemicals
from distinct regions of the developing brain (21,22). At high
magnetic field strengths, such as 9.4 T, neurotransmitter and
amino acid concentrations, as well as metabolite markers of
energy status, myelination and neuronal integrity, can be
reliably measured longitudinally from well-defined brain re-
gions, including the developing hippocampus (21).
The objective of the present study was to evaluate the effect
of fetal and neonatal iron deficiency on selected metabolite
concentrations in the developing hippocampus from postnatal
day (PD)4 7 to PD28 using high field 1H NMR spectroscopy.
We hypothesized that perinatal iron deficiency would alter the
developmental trajectories of select metabolites that are de-
pendent on intact iron metabolism. This novel technical
approach would allow for sequential in vivo tracking of the
metabolite changes as they appear over time.
MATERIALS AND METHODS
Animal preparation. All experiments were approved by the
Animal Care and Use Committee of the University of Minnesota.
Iron-deficient and iron-sufficient male and female Sprague-Dawley
rat pups (Harlan Sprague Dawley, Indianapolis, IN) between the ages
of PD7 and PD28 [weight range: 13 g (PD7) to 113 g (PD28)] were
used in the study. As in our previous studies (9,19), fetal and neonatal
iron deficiency was induced by feeding pregnant dams a low iron diet
(Formula TD 80396; Harlan-Teklad, Madison, WI; elemental iron
concentration: 3–6 mg/kg) from gestational d 2 to PD7, followed by
an iron-supplemented diet (Teklad 4% Mouse/Rat Diet 7001, Har-
lan-Teklad; elemental iron: 198 mg/kg) until PD28. The composi-
tions of the diets were published previously (16,19). The iron-suffi-
cient dams were fed the iron-supplemented diet throughout the
experiment. The litters were culled to 8 pups soon after birth to
ensure uniform growth. Rats had free access to food and water and
were maintained on a 12-h light:dark cycle at room temperature. A
total of 32 pups (8 per group on PD7 and PD28) from 4 litters (2
iron-sufficient and 2 iron-deficient) were utilized for tissue iron assay;
34 (18 iron-deficient and 16 iron-sufficient) pups from 8 litters (5
iron-deficient and 3 iron-sufficient) were studied by 1H NMR spec-
troscopy on PD7, PD10, PD14, PD21 and PD28. The regional neu-
rochemical profiles during brain development in these iron-sufficient
rats were reported previously (21). Six rats in each group were studied
longitudinally (i.e., on all 5 postnatal days); the remainder were
studied in a cross-sectional manner, resulting in 10–14 spectra in the
iron-deficient group and 8–12 spectra in the iron-sufficient group on
each of the 5 postnatal days.
Tissue iron assay. Tissue iron concentrations of the brain, liver
and heart were assayed by atomic absorption spectroscopy as previ-
ously described (19). Values were expressed as mol elemental iron/g
wet tissue weight. Brain water content was determined by weighing
the brain before and after drying for 72 h and was represented as a
percentage of wet weight.
NMR methods. 1H NMR spectra were obtained from spontane-
ously breathing rats under inhalation anesthesia (1–2% Isoflurane in
an equal mixture of O2 and N2O) using a horizontal bore 9.4 T/31 cm
magnet (Magnex Scientific, Abingdon, UK) interfaced to a Varian
INOVA console (Varian, Palo Alto, CA). The detailed technical
aspects of the NMR spectroscopy were described previously (21).
Briefly, field homogeneity was optimized using the FASTMAP shim-
ming technique (23,24). Spectroscopic localization was performed by
an ultrashort echo time single-voxel stimulated-echo acquisition
mode sequence (echo time  2 ms, mixing time  20 ms, repetition
time  5 s) combined with outer volume suppression and variable
pulse power and optimized relaxation water suppression (25). Posi-
tioning of the volume of interest (VOI) was based on multislice rapid
acquisition with relaxation enhancement imaging (echo train length
 8, echo time  48 ms, field of view  2  2 cm, matrix  256
 256, slice thickness  1 mm). The VOI (11–24 L) was adjusted
to match the postnatal increase in hippocampal size. The study of a
single rat did not exceed 60 min.
Quantification of metabolites. In vivo 1H NMR spectra were
analyzed using LCModel (26) as in our previous studies (21,27). The
signals of macromolecules and the following 18 metabolites were
quantified from each spectrum: alanine, aspartate, creatine (Cr),
-aminobutyric acid (GABA), glucose, glutamate, glutamine, gluta-
thione, glycerophosphorylcholine (GPC), lactate, myo-inositol, N-
acetylaspartate (NAA), N-acetylaspartylglutamate, phosphocreatine
(PCr), phosphorylcholine (PCho), phosphorylethanolamine, scyllo-
inositol and taurine, and were represented as mol/g. Scyllo-inositol
was not further analyzed because it was detected in only 25% of the
processed spectra in both groups. The sum of PCho and GPC
(PChoGPC) was used in the statistical analysis because of a strong
cross-correlation between these compounds due to their close spectral
similarity. Thus, the spectroscopy analysis resulted in 16 metabolites
that could be reliably quantified from the averaged spectra from every
rat. The ratios of phosphocreatine to creatine (PCr/Cr) and gluta-
mate/glutamine were also calculated.
Statistical methods. Group means of body and brain weights,
brain water content, hematocrit and tissue iron concentrations be-
tween the two groups were compared at PD7 (end of iron-deficient
dietary period) and PD28 (end of iron supplementation in the study)
using two-tailed t tests. Within each group, the differences between
PD7 and PD28 were compared using paired t tests. Metabolite con-
centrations were compared across time and between groups using
univariate ANOVA. Univariate analyses were employed instead of a
multivariate approach because the focus of the study was to examine
group differences in individual metabolites, not differences in the
weighted effect of metabolites in combination. Metabolite concen-
trations of rats studied longitudinally and in a cross-sectional manner
were comparable at each time point in both groups. Thus, data from
all rats at each time point were assessed together. A statistical analysis
software package (SPSS, Version 10.1; SPSS, Chicago, IL) was used
for all analyses. Data are presented as means  SD. A P-value  0.05
was considered significant.
RESULTS
General. Compared with the iron-sufficient group, the
iron-deficient group had higher body and brain weights on
PD7 and lower body and brain weights on PD28 (Table 1).
Brain water content was 87% on PD7 and 80% on PD28 in
both groups. The iron-deficient group had a lower hematocrit
4 Abbreviations: Cr, creatine; GABA,  -aminobutyric acid; GPC, glycerophos-
phorylcholine; NAA, N-acetylaspartate; NMDA, N-methyl-D-aspartate; PCr, phos-
phocreatine; PCr/Cr phosphocreatine to creatine ratio; PCho, phosphorylcholine;
PD, postnatal day; VOI, volume of interest.
TABLE 1
Effect of maternal dietary iron treatment during gestation and
early postnatal period on body weight and brain weight of









Iron-sufficient 7 14.2  0.7 0.56  0.03
28 97.5  11.1 1.14  0.03
Iron-deficient 7 16.6  0.8* 0.61  0.05*
28 83.6  7.2* 1.05  0.09*
1 Data are means  SD, n  8. Means differed within each group,
P  0.001. * Different from the iron-sufficient group, P  0.02.
2 Wet weight of the brain after removal of the cerebellum and brain
stem.
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on PD7 and a higher level on PD28 (Table 2). In the iron-
deficient group, brain iron concentrations were lower on both
PD7 and PD28, and liver and heart iron concentrations were
lower on PD7.
Hippocampal metabolite concentrations. There were sig-
nificant changes in the 1H NMR spectra between PD7 and
PD28 (Fig. 1). The “neurochemical profile” consisted of 16
metabolites that could be reliably quantified from the spectra.
The Cramer-Rao lower bounds, which estimate the accuracy
of the fitted concentrations, were below 20% for most metab-
olites at all postnatal ages in both groups. This corresponded to
an estimated error of calculated concentration  0.2 mol/g.
Only a few weakly selected metabolites, such as aspartate and
glucose, were quantified with an estimated error 0.3 mol/g.
As in the iron-sufficient group (21), 12 of the 16 metabo-
lites demonstrated significant changes in their concentrations
with increasing postnatal age in the iron-deficient group (Figs.
2–4) (P  0.001 for each metabolite). Iron deficiency had a
significant effect on the concentrations of 7 of these 12 me-
tabolites.
The maximum effect of iron deficiency over time was on
PCr, glutamate, NAA concentrations and the PCr/Cr ratio, all
of which were elevated in the iron-deficient group (all P
 0.002) (Fig. 2). Iron deficiency had a moderate effect on
aspartate, GABA, phosphorylethanolamine, taurine concen-
trations (Fig. 3) and the glutamate/glutamine ratio (data not
shown) over time (P  0.02 for taurine and P  0.005 for the
others). Glutamine, Cr, myo-inositol, PChoGPC (Fig. 4)
and alanine (data not shown) concentrations changed with
postnatal age but were not affected by iron deficiency.
DISCUSSION
Neurochemical changes accompany structural changes dur-
ing regional brain development. We demonstrated previously
that 1H NMR spectroscopy at 9.4 T can accurately measure
changes in the concentrations of 16 metabolites in three
specific brain regions in developing rats (21). In the present
study, we used this method successfully to demonstrate the
effect of perinatal iron deficiency on this neurochemical profile
in the developing hippocampus.
In the current study, the severity of brain iron deficiency
was slightly greater than that described in human infants with
perinatal iron deficiency (2,3). As demonstrated by studies in
humans (4,5) and rats (9,16,28), this degree of perinatal iron
deficiency affects the structure and function of the developing
hippocampus. Similarly, unmet hippocampal iron demands
were probably responsible for the neurochemical alterations in
the present study. Even though the iron-deficient rats were
anemic, cerebral hypoxia secondary to anemia is unlikely to
have played a major role in these neurochemical changes.
Gestational iron deficiency does not result in fetal hypoxia
(29). Furthermore, neurochemical alterations due to chronic
postnatal hypoxia differ from those observed in the present
study (30). Finally, the neurochemical changes persisted in the
iron-deficient group after anemia was adequately corrected.
FIGURE 1 Coronal brain section (A) and MRI (B) on postnatal day
(PD) 7, and 1H NMR spectra on PD7 (C) and PD28 (D) of the iron-
deficient rat hippocampus. The brain section (15 m) was stained for
cytochrome c oxidase activity. The 1H NMR spectra are from a volume
of 13.5 L (PD7) and 18 L (PD28) and represent an average of 160
scans each. Abbreviations: Asp, aspartate; Cr, creatine; GABA,  -ami-
nobutyric acid; Glu, glutamate; GPC, glycerophosphorylcholine; Ins,
myo-inositol; Lac, lactate; NAA, N-acetylaspartate; NAAG, N-acetylas-
partylglutamate; PCr, phosphocreatine; PCho, phosphorylcholine; PE,
phosphorylethanolamine; VOI, volume of interest.
TABLE 2
Effect of maternal dietary iron treatment during gestation and early postnatal period on hematocrit and tissue iron concentrations
of iron-deficient and iron-sufficient Sprague-Dawley rats1
Group Postnatal age Hematocrit
Tissue iron concentration
Brain Liver Heart
d % mol/g wet weight
Iron-sufficient 7 32.8  2.9 0.10  0.02 2.99  0.63a 0.45  0.10a
28 39.3  1.4 0.18  0.01 2.38  1.14a 0.51  0.14a
Iron-deficient 7 17.4  1.5* 0.04  0.01* 0.27  0.06* 0.23  0.02*
28 44.8  2.1* 0.15  0.01* 2.70  1.15 0.44  0.15
1 Data are means  SD, n  8. For each group, means without a common letter differ, P  0.005. * Different from the iron-sufficient group,
P  0.02.
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The deleterious effects of iron deficiency have been postu-
lated to be mediated through multiple biochemical pathways
in which iron and iron-containing enzymes play important
roles (8,31,32). The temporal evolution of the neurochemical
profile of the iron-deficient hippocampus paralleled that of
iron-sufficient rats, yet the two profiles were not identical.
FIGURE 3 Effect of maternal dietary iron treatment during gesta-
tion and early postnatal period on aspartate, -aminobutyric acid
(GABA), phosphorylethanolamine and taurine concentrations between
postnatal days 7 and 28 in iron-deficient and iron-sufficient Sprague-
Dawley rats. The iron-sufficient data were published previously (21).
Values are means  SD, n  8–12 (iron-sufficient) and 10–14 (iron-
deficient) at each postnatal age. *Different over time for each group, P
 0.001; #different between groups over time, P  0.02 for taurine, and
P  0.005 for the others.
FIGURE 2 Effect of maternal dietary iron treatment during gesta-
tion and early postnatal period on phosphocreatine concentration, the
phosphocreatine/creatine ratio (PCr/Cr), glutamate and N-acetylaspar-
tate concentrations between postnatal days 7 and 28 in iron-deficient
and iron-sufficient Sprague-Dawley rats. The iron-sufficient data were
published previously (21). Values are means  SD, n  8–12 (iron-
sufficient) and 10–14 (iron-deficient) at each postnatal age. *Different
over time for each group, P  0.001; #different between groups over
time, P  0.002.
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Elevations in the concentrations of multiple metabolites in the
iron-deficient group could suggest changes in tissue architec-
ture, slightly different quantification conditions or temporal
shifts in hippocampal development in perinatal iron defi-
ciency. However, such scalar reasons for the concentration
elevations in the present study can be ruled out because the
magnitudes of elevation were not uniform across all metabo-
lites and the concentrations of some metabolites with strong
postnatal developmental changes, such as myo-inositol, did
not differ between the groups. This implies that although the
overall progression of hippocampal development may not be
altered by perinatal iron deficiency in a major way, substantial
deviations occur in its neurochemical profile during this pro-
cess.
Perinatal iron deficiency resulted in elevated PCr and
PCr/Cr ratio, i.e., a higher phosphorylation potential (Fig. 2).
These findings most likely indicate altered energy metabolism.
PCr is a readily releasable cytosolic store of high energy phos-
phate for ATP synthesis with excess ATP being converted to
PCr for energy storage (33,34). Because iron deficiency ad-
versely affects oxidative production of ATP (8,9), a decrease
in PCr concentration would have been expected in perinatal
iron deficiency. However, unlike acute injuries, chronic ad-
verse conditions result in complete recovery of PCr concen-
trations, even when ATP concentrations are restored only
partially (35,36). The elevated PCr/Cr ratio in the setting of
chronic iron deficiency may therefore reflect a compensatory
mechanism to sustain ATP production during periods of in-
creased energy demand. However, this protective effect is
likely to be transient because the perinatally iron-deficient
hippocampus is highly vulnerable to superimposed acute hy-
poxic-ischemic injury (19). Finally, because the measurement
of PCr by NMR spectroscopy is not neuron specific, the
elevated PCr levels may also reflect altered oligodendrocyte
energy function in perinatal iron deficiency. In demyelinating
disorders, PCr levels are elevated (37).
Altered neuronal energy metabolism may also be responsi-
ble for the elevated glutamate concentrations in the iron-
deficient group (Fig. 2). The majority of glutamate measured
by 1H NMR spectroscopy was localized to the neuronal com-
partment (38). Thus, the elevated glutamate concentrations
suggest either increased synthesis or relatively decreased re-
lease of glutamate from the neurons. Glutamate plays an
important role in neurodevelopment through its stimulatory
effect on N-methyl-D-aspartate (NMDA) receptors (39–41).
Glutamate-glutamine cycling between neuron and glia has
been accepted as the major mechanism for maintaining glu-
tamatergic neurotransmission (42–44). Glutamatergic neuro-
transmission is a highly energy-dependent process that ac-
counts for 80% of the total energy expenditure in the brain
(45). We postulate that glutamatergic neurotransmission is
decreased in perinatal iron deficiency as a result of inefficient
energy metabolism and is responsible for the elevated intra-
cellular glutamate levels. The elevated glutamate/glutamine
ratio in the present study, the reduced expression of NR2b
subunit of the NMDA receptors in the perinatally iron-defi-
cient hippocampus (28) and the reduced glutamate binding to
synaptic membranes in iron deficiency states (46) support this
postulation. Our working hypothesis is that decreased gluta-
matergic neurotransmission during development is responsible
for the abnormal dendritic arborization recently demonstrated
in the hippocampus in perinatal iron deficiency (28).
Aspartate and GABA levels were also elevated in the
iron-deficient rats (Fig. 3). Like glutamate, aspartate and
GABA were postulated to stimulate dendritic arborization and
synaptic plasticity in the developing brain (39,41,47,48).
However, beyond PD7, the GABAergic neurotransmission
switches from excitatory to inhibitory in the hippocampus
(47). Thus, the increased GABA levels may suggest an in-
creased inhibitory drive for reducing the overall neurotrans-
FIGURE 4 Effect of maternal dietary iron treatment during gestation
and early postnatal period on glutamine, creatine, myo-inositol and com-
bined phosphorylcholine and glycerophosphorylcholine (PChoGPC)
concentrations between postnatal days 7 and 28 in iron-deficient and
iron-sufficient Sprague-Dawley rats. The iron-sufficient data were pub-
lished previously (21). Values are means  SD, n  8–12 (iron-sufficient)
and 10–14 (iron-deficient) at each postnatal age. *Different over time for
each group, P  0.001.
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mission rates and brain activity in an energy-limited environ-
ment. Both decreased glutamatergic stimulation of NMDA
receptors and increased GABAergic inhibitory neurotransmis-
sion are associated with impairments in hippocampally based
memory tasks in rats (49). We speculate that such a mecha-
nism may be responsible for the abnormalities in hippocam-
pus-specific cognitive tasks in rats (16) and the electrophysi-
ologic tests of recognition memory in human infants with
perinatal iron deficiency (4,5).
The mean NAA concentration was higher in the iron-
deficient rats (Fig. 2). NAA, synthesized and stored primarily
in the neurons, plays a major role in myelin synthesis in the
developing brain (50–53). Deacetylation of NAA for myelin
synthesis requires optimal functioning of the oligodendrocytes
(54). Oligodendrocytes have one of the highest metabolic
rates and require considerable amounts of iron for myelin
synthesis and oxidative phosphorylation (11). Although the
neuronal number and distribution are not affected by gesta-
tional iron deficiency (55), the production, and presumably
function of oligodendrocytes is decreased (56). Early iron
deficiency results in reduced total myelin and phospholipid
content of the brain (57,58). Thus, in the present study,
increased NAA levels may represent decreased utilization of
the compound for myelination. A similar mechanism may also
be responsible for the elevated phosphorylethanolamine levels
in the iron-deficient group in the present study (Fig. 3). As a
precursor of phosphatidylethanolamine, a major phospholipid
in the brain (59), phosphorylethanolamine levels decrease
with the onset and progression of myelination in humans and
rats (37,60). Hypomyelination is postulated to be responsible
for the persistent abnormalities in the auditory and visual
evoked potentials demonstrated in human infants with early
iron deficiency (61,62).
In summary, the present study suggests that perinatal iron
deficiency significantly altered the neurochemical profile of
the developing hippocampus. The ability to sequentially track
neurochemical changes reliably as they unfolded attests to the
sensitivity of high field 1H NMR spectroscopy for evaluating
regional brain development under typical and adverse condi-
tions. Because it is noninvasive, the method may be extended
for similar studies in human infants. Changes in various me-
tabolites suggest that multiple iron-dependent biochemical
pathways may be involved in perinatal iron deficiency and
compound its adverse effects on neurodevelopment. Their
reversibility with iron rehabilitation, as well as their effects on
neuronal function and behavior, has yet to be studied. Nev-
ertheless, the findings of the present study may provide plau-
sible biochemical explanations for the electrophysiologic and
neurodevelopmental abnormalities observed in human infants
with perinatal brain iron deficiency.
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